TrialThe Lancet. Oncology2013

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study.

Sandra M Swain et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.